Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 in Kaposi Sarcoma
NCT04893018Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efineptakin alfa in Kaposi sarcoma (KS), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Percentage of Participants With Adverse Events. Started May 2022; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT04893018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893018.